Search

Gregory J Stahl

from Ravenna, MI
Age ~36
Get Report
Also known as:
Gregory James Stahl, Greg Stahl
Phone and address:
4633 Wunsch Rd, Ravenna, MI 49451
(219) 869-7205
Related to:
Marjie Den Dulk, 63Jessica N Prairie, 40Timothy Barlow, 43Timm Prairie, 73William Sharp
Connected to:
Adrienne Stahl, 49Allison Stahl, 30Angela Stahl, 36Anita B Stahl, 50Antoine L Stahl, 53Arica J Stahl, 37Audra Stahl, 56Betty Stahl, 50Briar K Stahl, 45Bridget K Stahl, 69

Gregory Stahl Phones & Addresses

  • 4633 Wunsch Rd, Ravenna, MI 49451 (219) 869-7205
  • Demotte, IN
  • Whitinsville, MA
  • Sioux Center, IA

Skills

Leadership • Management • Research • Public Speaking • Community Outreach • Strategic Planning

Professional Records

Medicine Doctors

Gregory Stahl Photo 1

Gregory D. Stahl

View page
Specialties:
Internal Medicine
Work:
Center For Mens Health
401 Commercial Ct STE D, Venice, FL 34292
(941) 870-2250 (phone), (941) 485-8404 (fax)
Education:
Medical School
Albany Medical College
Graduated: 1979
Procedures:
Electrocardiogram (EKG or ECG)
Vaccine Administration
Conditions:
Bronchial Asthma
Diabetes Mellitus (DM)
Disorders of Lipoid Metabolism
Hypothyroidism
Acne
Languages:
English
Description:
Dr. Stahl graduated from the Albany Medical College in 1979. He works in Venice, FL and specializes in Internal Medicine.

Resumes

Resumes

Gregory Stahl Photo 2

Gregory Stahl

View page
Skills:
Leadership
Management
Research
Public Speaking
Community Outreach
Strategic Planning

Business Records

Name / Title
Company / Classification
Phones & Addresses
Gregory Stahl
Owner
Stahl's Farm Backhoes
Trucking Operator-Nonlocal
135 Everett St, Wrentham, MA 02093
Gregory R. Stahl
SPICE BARN, INC
Gregory L. Stahl
Principal
WAGNER & GRISWOLD SOCIETY, INC
Nonprofit Trust Management
290 Chestnut St, Clinton, MA 01510

Publications

Us Patents

Methods And Products For Regulating Lectin Complement Pathway Associated Complement Activation

View page
US Patent:
7273925, Sep 25, 2007
Filed:
Dec 15, 1999
Appl. No.:
09/464303
Inventors:
Gregory L. Stahl - Clinton MA, US
Charles D. Collard - Wellesley MA, US
Assignee:
Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
C12P 21/08
C07K 16/18
C12N 5/20
A61K 39/395
US Classification:
5303873, 53038825, 5303893, 530866, 435325, 435328, 435337, 435346, 4241331, 4241451, 424809
Abstract:
The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are accomplished by contacting a mammalian cell having surface exposed MBL ligand with an effective amount of a mannan binding lectin inhibitor to inhibit lectin complement pathway associated complement activation. The mannan binding lectin inhibitor may be administered to a subject to prevent cellular injury mediated by lectin complement pathway associated complement activation. The products of the invention include compositions of a mannan binding lectin inhibitor. The mannan binding lectin inhibitor is an isolated mannan binding lectin binding peptide that selectively binds to a human mannan binding lectin epitope and that inhibits lectin complement pathway associated complement activation. The products also include hybridoma cell lines and pharmaceutical compositions.

Lectin Complement Pathway Assays And Related Compositions And Methods

View page
US Patent:
8524453, Sep 3, 2013
Filed:
Feb 9, 2007
Appl. No.:
12/223763
Inventors:
Gregory L. Stahl - Clinton MA, US
Mary C. Walsh - Brighton MA, US
Assignee:
The Brigham and Woman's Hospital, Inc. - Boston MA
International Classification:
G01N 33/53
US Classification:
435 71, 436518
Abstract:
This invention is related, in part, to assays for analyzing the lectin complement pathway (LCP) as well as to compositions and methods related thereto.

Methods And Products For Regulating Lectin Complement Pathway Associated Complement Activation

View page
US Patent:
20040259771, Dec 23, 2004
Filed:
Jan 28, 2004
Appl. No.:
10/766755
Inventors:
Gregory Stahl - Clinton MA, US
Charles Collard - Houston TX, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
A61K038/16
US Classification:
514/008000
Abstract:
The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are accomplished by contacting a mammalian cell having surface exposed MBL ligand with an effective amount of a mannan binding lectin inhibitor to inhibit lectin complement pathway associated complement activation. The mannan binding lectin inhibitor may be administered to a subject to prevent cellular injury mediated by lectin complement pathway associated complement activation. The products of the invention include compositions of a mannan binding lectin inhibitor. The mannan binding lectin inhibitor is an isolated mannan binding lectin binding peptide that selectively binds to a human mannan binding lectin epitope and that inhibits lectin complement pathway associated complement activation. The products also include hybridoma cell lines and pharmaceutical compositions.

C1Q Complement Inhibitors And Methods Of Use Thereof

View page
US Patent:
20050019326, Jan 27, 2005
Filed:
Jun 16, 2004
Appl. No.:
10/869823
Inventors:
Gregory Stahl - Clinton MA, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
A61K039/395
C12N005/06
US Classification:
424145100, 530388250, 435326000
Abstract:
The present invention relates to agents that bind and/or inhibit classical complement C1 subcomponent, C1q, as well as methods of their use. In particular, the invention relates to methods for inhibiting classical complement activation by contacting a C1q molecule with a C1q inhibitor. The invention, therefore, also relates to methods for treating disorders using the C1q inhibitors described herein. More specifically, the C1q inhibitors provided can be used to treat any condition mediated by the classical complement system. More specifically, the C1q inhibitors can be used to treat inflammatory conditions and the resulting tissue injury, autoimmune disorders and cancer.

Methods And Compositions For The Regulation Of Lectin Complement Pathway (Lcp)-Associated Complement Activation In Hyperglycemic Myocardial Damage

View page
US Patent:
20110293524, Dec 1, 2011
Filed:
Feb 29, 2008
Appl. No.:
12/920176
Inventors:
Gregory L. Stahl - Clinton MA, US
Assignee:
The Brigham and Women"s Hosptial Inc. - Boston MA
International Classification:
A61K 49/00
C12Q 1/02
A61K 38/02
A61P 9/10
A61K 39/395
A61P 9/00
A61P 43/00
C12N 5/071
A61K 31/713
US Classification:
424 92, 435375, 435 29, 514 164, 514 44 A, 4241521, 514 11
Abstract:
The present invention relates to methods and compositions for regulating lectin complement pathway (LCP)-associated complement activation. In particular, the invention relates to methods and compositions for inhibiting LCP-associated complement activation in order to inhibit hyperglycemic myocardial damage. The invention also relates to the treatment of cardiomyopathy and/or hypertrophy, such as cardiac hypertrophy. The invention also relates to methods and compositions for inhibiting the loss of cardiac progenitor cells by inhibiting LCP-associated complement activation. The methods include both in vitro and in vivo methods. The methods can be accomplished by contacting a mammalian cell having a surface exposed mannose binding lectin (MBL) ligand, such as a cardiac cell, with an effective amount of a MBL inhibitor to inhibit LCP-associated complement activation.
Control profile
Gregory J Stahl from Ravenna, MI, age ~36 Get Report